Lion Point Capital’s Cymabay Therapeutics CBAY Stock Holding History

Lion Point Capital’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-82,425	Closed	-$1.95M	–	37
2023 Q4	$1.95M	Hold	82,425	–	–	0.97%	12
2023 Q3	$1.23M	Sell	82,425 -17,000	-17%	-$225K	0.55%	14
2023 Q2	$1.09M	Hold	99,425	–	–	0.49%	16
2023 Q1	$867K	Sell	99,425 -120,000	-55%	-$961K	0.36%	21
2022 Q4	$704K	Hold	219,425	–	–	0.1%	28
2022 Q3	$704K	Buy	+219,425	New	+$788K	0.16%	35

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Lion Point Capital's CBAY Position: Q1 2024 in Review

Lion Point Capital sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 82,425 shares — an estimated $1.95M sold.

Lion Point Capital first reported a position in CBAY in Q3 2022 and held it in 6 quarters. The position peaked at $1.95M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Lion Point Capital reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Lion Point Capital sold 82,425 Cymabay Therapeutics shares in Q1 2024, an estimated $1.95M.
Lion Point Capital first reported a position in Cymabay Therapeutics in Q3 2022 and held it in 6 quarters.
Lion Point Capital's Cymabay Therapeutics position peaked at $1.95M in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Lion Point Capital's 13F filing for Q1 2024, filed 15 May 2024.